180 related articles for article (PubMed ID: 20026117)
1. Ion channels in T lymphocytes: an update on facts, mechanisms and therapeutic targeting in autoimmune diseases.
Varga Z; Hajdu P; Panyi G
Immunol Lett; 2010 May; 130(1-2):19-25. PubMed ID: 20026117
[TBL] [Abstract][Full Text] [Related]
2. Ion channels in T cells: from molecular pharmacology to therapy.
Krasznai Z
Arch Immunol Ther Exp (Warsz); 2005; 53(2):127-35. PubMed ID: 15928581
[TBL] [Abstract][Full Text] [Related]
3. Potassium channels as therapeutic targets for autoimmune disorders.
Wulff H; Beeton C; Chandy KG
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):640-7. PubMed ID: 14579513
[TBL] [Abstract][Full Text] [Related]
4. Functional consequences of Kv1.3 ion channel rearrangement into the immunological synapse.
Tóth A; Szilágyi O; Krasznai Z; Panyi G; Hajdú P
Immunol Lett; 2009 Jun; 125(1):15-21. PubMed ID: 19477198
[TBL] [Abstract][Full Text] [Related]
5. Toxins Targeting the Kv1.3 Channel: Potential Immunomodulators for Autoimmune Diseases.
Zhao Y; Huang J; Yuan X; Peng B; Liu W; Han S; He X
Toxins (Basel); 2015 May; 7(5):1749-64. PubMed ID: 25996605
[TBL] [Abstract][Full Text] [Related]
6. Ion channels and lymphocyte activation.
Panyi G; Varga Z; Gáspár R
Immunol Lett; 2004 Mar; 92(1-2):55-66. PubMed ID: 15081528
[TBL] [Abstract][Full Text] [Related]
7. Biophysical and pharmacological aspects of K+ channels in T lymphocytes.
Panyi G
Eur Biophys J; 2005 Aug; 34(6):515-29. PubMed ID: 16184309
[TBL] [Abstract][Full Text] [Related]
8. [Ion channels on T lymphocyte].
Xiao L; Fu HY; Song DM; Fan SG
Sheng Li Ke Xue Jin Zhan; 2003 Apr; 34(2):105-10. PubMed ID: 12889140
[TBL] [Abstract][Full Text] [Related]
9. Ion channels as potential targets for the treatment of depression.
Lodge NJ; Li YW
Curr Opin Drug Discov Devel; 2008 Sep; 11(5):633-41. PubMed ID: 18729015
[TBL] [Abstract][Full Text] [Related]
10. Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
Bagdány M; Batista CV; Valdez-Cruz NA; Somodi S; Rodriguez de la Vega RC; Licea AF; Varga Z; Gáspár R; Possani LD; Panyi G
Mol Pharmacol; 2005 Apr; 67(4):1034-44. PubMed ID: 15615696
[TBL] [Abstract][Full Text] [Related]
11. Morphological changes of T cells following formation of the immunological synapse modulate intracellular calcium signals.
Quintana A; Kummerow C; Junker C; Becherer U; Hoth M
Cell Calcium; 2009 Feb; 45(2):109-22. PubMed ID: 18789821
[TBL] [Abstract][Full Text] [Related]
12. Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels.
Koo GC; Blake JT; Shah K; Staruch MJ; Dumont F; Wunderler D; Sanchez M; McManus OB; Sirotina-Meisher A; Fischer P; Boltz RC; Goetz MA; Baker R; Bao J; Kayser F; Rupprecht KM; Parsons WH; Tong XC; Ita IE; Pivnichny J; Vincent S; Cunningham P; Hora D; Feeney W; Kaczorowski G
Cell Immunol; 1999 Nov; 197(2):99-107. PubMed ID: 10607427
[TBL] [Abstract][Full Text] [Related]
13. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
Schmitz A; Sankaranarayanan A; Azam P; Schmidt-Lassen K; Homerick D; Hänsel W; Wulff H
Mol Pharmacol; 2005 Nov; 68(5):1254-70. PubMed ID: 16099841
[TBL] [Abstract][Full Text] [Related]
14. Ion Channels as Therapeutic Targets--CHI's Fourth Annual Conference.
Thorneloe KS
IDrugs; 2010 Jan; 13(1):16-9. PubMed ID: 20024841
[TBL] [Abstract][Full Text] [Related]
15. The role of supramolecular protein complexes and membrane potential in transmembrane signaling processes of lymphocytes.
Vámosi G; Bodnár A; Damjanovich S; Nagy P; Varga Z; Damjanovich L
Immunol Lett; 2006 Apr; 104(1-2):53-8. PubMed ID: 16378646
[TBL] [Abstract][Full Text] [Related]
16. Ion channel modulators: new targets and new indications for old targets.
Priest B; Kaczorowski GJ; Garcia ML
Curr Opin Drug Discov Devel; 2006 Sep; 9(5):587-94. PubMed ID: 17002219
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte calcium influx characteristics and their modulation by Kv1.3 and IKCa1 channel inhibitors in healthy pregnancy and preeclampsia.
Toldi G; Stenczer B; Treszl A; Kollár S; Molvarec A; Tulassay T; Rigó J; Vásárhelyi B
Am J Reprod Immunol; 2011 Feb; 65(2):154-63. PubMed ID: 20649894
[TBL] [Abstract][Full Text] [Related]
18. Potassium channels in T lymphocytes: therapeutic targets for autoimmune disorders?
Vianna-Jorge R; Suarez-Kurtz G
BioDrugs; 2004; 18(5):329-41. PubMed ID: 15377175
[TBL] [Abstract][Full Text] [Related]
19. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.
Rangaraju S; Chi V; Pennington MW; Chandy KG
Expert Opin Ther Targets; 2009 Aug; 13(8):909-24. PubMed ID: 19538097
[TBL] [Abstract][Full Text] [Related]
20. Ion channel blockers for the treatment of neuropathic pain.
Colombo E; Francisconi S; Faravelli L; Izzo E; Pevarello P
Future Med Chem; 2010 May; 2(5):803-42. PubMed ID: 21426204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
